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ABSTRACT 
A new reverse phase HPLC method for simultaneous estimation of Aspirin and Omeprazole in rat plasma was developed and validated. The 
separation was achieved on Hypersil ODS C18 column. The mobile phase Acetonitrile: Methanol: 0.05M Phosphate buffer (40:5:55) was 
delivered at a flow rate of 1ml/min. The Eluent was monitored using spectrophotometric detection at 225nm. The relationship between Aspirin 
and Omeprazole and peak height ratio was linear over the range of 5-15µg/ml and 3-8.7µg/ml respectively. Percentage recovery for Aspirin 
was 100.02 and Omeprazole was 99.66. The Tmax for Aspirin was 1hr 20mins and for Omeprazole was 1hr 15mins respectively. Prepared 
Aspirin and Omeprazole levels after oral administration of a therapeutic dosage were 3.1ug/ml and 1.8µg/ml indicating that the described 
method is potentially suitable for TDM. 
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Introduction 
Yosprala is an only sequentially designed therapy in 
combination of aspirin and omeprazole for preventing 
gastric ulcers produced by aspirin used to prevent cardio 
and cerebrovascular events. Aspirin is a salicylate which acts 
as on the substances by reducing pain, fever and 
inflammation. Omeprazole is a proton pump inhibitor which 
acts by decreasing the production of acid secretion in the 
stomach. Yosprala is a platelet aggregation inhibitor. Thus, it 
is used to lower the various cardiac problems such as strokes 
or death. 
In certain conditions the problems are related to blood clots, 
angina, past heart attack and stroke or mini strokes. To 
improve the blood flow to the heart for the patients who had 
surgery are treated with yosprala. Omeprazole in this 
combination acts to reduce the gastric ulcers produced by 
aspirin. The individual dosage of aspirin and omeprazole will 
not have same therapeutic activity as of combination as 
yosprala. [1] Yosprala [fig-1] is a combination of salicylate and 
proton pump inhibitor, chemically it is called as yosprala; 
aspirin/omeprazole; omeprazole/aspirin; aspirin with the 
mixture of yosprala. IUPAC name of yosprala is 2acetyloxy 
benzoic acid; 6-methoxy-2-[(4-methoxy-3, 5-dimethyl 
pyridine-2-yl methyl sulfinyl]-H-benzimidazole. Its 
molecular weight is 525.576g/mol, corresponding to the 
molecular formula C26H27N307S. It is freely soluble in 
methanol and water and partially soluble in ethanol and 
acids. [2] 
 
Fig-1 . Structure of Yosprala 
Salomi et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2019; 9(3):332-338 
ISSN: 2250-1177                                                                                  [333]                                                                                 CODEN (USA): JDDTAO 
Yosprala is a delayed release tablet orally administered.One 
tablet of yosprala[fig-2] contains 1 strength of omeprazole 
and 2 strengths of aspirin in two different strengths as 
81/40, 325/40.It should be administered 1hour before meal 
and should be swallowed whole with liquid.It is mostly 
indicated for patients who require aspirin for secondary 
prevention of cardiovascular and cerebrovascular events and 
who are at high risk of producing gastric ulcers due to daily 
dosage of aspirin.It is highly caused in people above 55years 
of age and or patients having past ulcerative problems.[3]  
Mechanically as it is a combination drug aspirin acts as 
antiplatelet agent which inhibits the synthesis of 
prostaglandin and aggregation of platelets and omeprazole is 
a substituted benzimidazole which belongs to the class of 
antisecretory compounds.It shows its activity by suppresing 
the release og gastric acid by inhibiting the [H+/K+]ATPase 
enzyme which is responsible for production of gastric acid 
on the surface by parietal cells.Yosprala may cause side 
effects such as gastritis,diaarhoes,gastric polyps,nausea and 
non cardiac chest pain.[4] 
Because of it’s therapeutically importance quantitative 
determination of yosprala is very significant in 
pharmaceuticals and human physiological fluids for both 
quality control of preparations and chemical diagnosis. In the 
last years many methods have been reported for the 
determination of aspirin and omeprazole individually and 
very few attempts have been developed for estimation of 
yosprala. The current reviews surveys the methods 
developed to determine yosprala in drug products.
 
 
Fig-2. Yosprala capsule 
 
Methods for pharmaceuticals 
Chromatographic Methods 
Performance characteristics of RP-HPLC Method  
S.No Stationary phase, Mobile Phase UV-
detection 
(nm) 
Linear range 
(µg/ml) 
 LOD  LOQ Application  Ref  
1 
 
C18 (150mm-3.0 mm,5 μm);  0.1M 
Dipotassium phosphate buffer 
(pH 3) and Methanol in the ratio 
of 40:60v/v   
246nm 10-50µg/ml for 
Aspirin and 50-
250µg/ml for 
Omeprazole 
9.24 µg/ml  10.37 
µg/ml 
Bulk and 
Dosage form  
[5] 
2 C8 (150×4.6, 5um) column 
quaternary gradient pump 
SP930D HPLC system. 
Acetonitrile:Methanol:Phosphate 
Buffer at pH 2.5 in the ratio 
25:10:65 
228nm 20-100μg/ml for -
AP10-50 μg /ml 
for -OMP 
1.23 μg/ml 
–ASP 
1.25 μg/ml-
OMP  
4.12 
μg/ml –
ASP, 
4.18 
μg/ml –
OMP 
Dosage  [6] 
3  C18  Ammonium Acetate 
Buffer+Acetonitrile+Methanol 
233nm  18-42μg/ml for -
ASP 
 6-14μg /ml for -
OMP 
2.880 μg/ml 
–ASP 
1.987- 
μg/ml – 
OMP.  
6.703 
μg/ml –
ASP 
4.630 
μg/ml - 
OMP. 
Tablet dosage 
form 
[7] 
4 C18 column,Acetonitriel-water 
(60:40v/v) 
240nm 10-100 μg/ml for 
–ASP 
4-80 μg/ml for -
OMP 
  Bulk powder 
and 
pharmaceutical 
formulation 
[8] 
5 Agilent C18 column, buffer Ph 240nm 10 μg/ml for –ASP 
10 μg/ml for -
0.1372  0.132-ASP Capsule dosage 
form 
[9] 
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UVvisible spectrophotometric method 
 
 
S.No.  
Diluent  λmax (nm) Linear range(mg/mL); 
molarextinction coefficient 
LOD LOQ Application  Ref  
1 Methanol  224.7nm- ASP 
251nm-OMP 
0.5-25µg/ml –ASP 1-8µg/ml 
-OMP 
1.08 µg/ml 3.27 µg/ml Bulk dosage 
form 
[15] 
2  274nm-ASP 
302nm-OMP 
25-125 μg/ml for- ASP 
3-15 μg/ml for-OMP 
 
  Laboratory 
Sample 
[16] 
 
The review of the analytical methods reported for Aspirin 
and Omeprazole [YOSPRALA] showed that UV-
spectrophotometric and RP-HPLC methods were developed 
and validated by using different solvents. The reported 
methods [17-23] are developed to determine Aspirin 
individually or in combination with other drugs and the 
methods [24-30] are developed to determine Omeprazole 
individually or in combination with other drugs using 
different techniques. No bio analytical method yet has been 
reported. Hence an attempt is made to develop a method for 
simultaneous estimation of Aspirin and Omeprazole in rat 
plasma and the proposed method was applied for 
pharmacokinetic study.  
 
 
Experimental  
Apparatus 
Chromatography was performed on Waters HPLC that 
includes photodiode array detector and an auto injector. A 
reverse phase Thermo scientific Hypersil 
ODS(250x4.6mm,5mm) Column in conjugation with guard 
packed pre-column and C18 insert were used for separation. 
Chemicals and Reagents 
All reagents were of analytical grade unless stated otherwise. 
Acetonitrile HPLC grade was supplied by Yarrow Chem 
Products Mumbai. Water for HPLC analysis were generated 
by RO, UV, MilliQ water. Aspirin,(CAS N0:50-78-
2),Potency:99% , Expiry:2/2020  Omeprazole (CAS 
NO:73590-58-6),Potency: 99% ,Expiry:  2/2020.   
3:Methanol(30:70) OMP -ASP 
3.17-OMP 
5.60-OMP 
6 Zorbax Eclipse XDB-
C18;Acetonitrile:water(50:50,v/v) 
293nm 8.1 μg/ml for –
ASP 
4 μg/ml for -OMP 
0.67 μg/ml 
for –ASP 
0.43 μg/ml 
for -OMP 
1.94 
μg/ml for 
–ASP 
1.25 
μg/ml for 
-OMP 
Bulk sample 
powder 
[10] 
7 C18 water 
xterra;water;Methanol(50:50v/v) 
244nm 81 μg/ml for –ASP 
40 μg/ml for -
OMP 
0.04517 
μg/ml for –
ASP 
0.003620 
μg/ml for -
OMP 
0.1369 
μg/ml for 
–ASP 
0.01097 
μg/ml for 
-OMP 
Synthetic 
mixture 
[11] 
8 Thermo C18 
column;Acetonitrile:phosphate 
buffer(70:30v/v) 
295nm 5-25 μg/ml for –
ASP 
5-25 μg/ml for -
OMP 
0.89 μg/ml 
for –ASP 
0.45 μg/ml 
for -OMP 
2.41 
μg/ml for 
–ASP 
1.25 
μg/ml for 
-OMP 
Bulk drug and 
Synthetic 
mixture 
[12] 
 
 
 
9 Zodiac C18 
column;0.1Mpotassium 
dihydrogen phosphate: 
Acetonitrile (55:45%v/v) 
260nm 0.65-195 μg/ml 
for –ASP 
0.08-24 μg/ml for 
-OMP 
0.199 μg/ml 
for –ASP 
0.024 μg/ml 
for -OMP 
0.650 
μg/ml for 
–ASP 
0.080 
μg/ml for 
-OMP 
Tablet dosage 
form 
[13] 
10 Cosmosil 
C18column;Methanol:Water 
(60:40) 
231nm 10-50 μg/ml for – 
ASP  
20-100 μg/ml for-
OMP 
 
0.5375 
μg/ml for-
ASP 
0.5946 
μg/ml for-
OMP 
1.6290 
μg/ml for-
ASP 
1.9820 
μg/ml for-
OMP 
Bulk and 
Dosage form 
[14] 
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Chromatographic Conditions  
The mobile phase consisted of 0.05M Phosphate buffer (Ph 4 
adjusted with 0.1% Tri ethyl Amine),Methanol and 
Acetonitrile in ( 55:5:40 ). Before delivering in to the system, 
the mobile phase was filtered through 0.45µm 
polytetrafluroethylene filter and Sonicated for 5min. The 
analysis was carried out under isocratic conditions using 
flow rate of 1ml/min at room temperature [260c]. 
Chromatograms were recorded at 225nm using photodiode 
array detector.  
Stock Solutions 
Stock solutions of aspirin and omeprazole were prepared by 
dissolving 10mg of aspirin and 5mg of omeprazole in 100ml 
of 0.05M phosphate buffer to enhance solubility. The solution 
was shaken completely by hand and Sonicated for 
10minutes. The concentration of both stock solutions were 
equivalent to 1000µg/ml concentrate of aspirin and 500 
µg/ml concentration of omeprazole [STOCK SOLUTION –A] 
1ml of stock solution of aspirin and omeprazole were added 
to 10ml of blank plasma to produce a solution with 
concentration of 100 µg/ml of aspirin and 50µg/ml of 
Omeprazole.[STOCK SOLUTION-B] 
Working Standards 
1ml of stock-B is added to 10ml of mobile phase to produce 
10 µg/ml concentration of Aspirin and 5µg/ml concentration 
of omeprazole. The solutions were vertexed for 1min and 
0.5ml aliquot was transferred to 1.5ml micro centrifuge 
tubes and stored at 20oc until used. 
Calibration Standard /Q.C. Samples 
 Calibration standards were prepared by mixing nine 
volumes of aspirin and omeprazole working solutions in the 
range of 2-40 µg/ml concentration for aspirin and 1-20 
µg/ml for Omeprazole. Six quality control samples were 
prepared mixing 0.5,1,2,3,4 and 5ml of stock-B solutions to 
10ml of blank rat plasma to yield concentrations of 5, 
10,20,30,40 and 50 µg/ml concentrations of aspirin and 
2.5,5,10,15,20 and 25 µg/ml concentrations of Omeprazole. 
The solutions were vertexed for 1ml then 0.5ml of aliquots 
were transferred to 1.5ml Eppendrof micro centrifuge tubes 
and stored at -200c until used. 
Sample Preparation 
 0.5ml of quality control samples were placed in 1.5ml micro 
centrifuge tubes. The solutions were vertexed for 30sec, 
Sonicated for 1min, transferred centrifree Micro partition 
system, precipitated using methanol and  centrifuged at 
3000rpm for 30min.0.1ml of ultra filtrate was injected in to 
chromatographic system using an auto sampler.   
Pharmacokinetic Study  
Animal 
A male albino rat(200g)housed under standard conditions 
and had a labium access to water and standard laboratory 
diet throughout the experiments were used in the present 
study. After a single dose by oral administration of 15mg/kg 
and 8mg/kg of Aspirin and Omeprazole, Blood samples were 
collected at regular intervals of time up to 24hrs. 
Preparation of ASP and OME oral doses 
ASP and OME was dissolved in water by using 1%Tween 80 
and 0.5% carboxyl methyl cellulose.ASP and OME were given 
to wistar rats with oral dose of 15mg/kg and 8mg/kg 
respectively.  
The developed IL-DLLME method was successfully used to 
quantification of Aspirin and Omeprazole concentration after 
15mg/kg oral administration of Aspirin and Omeprazole in 
six rats. The standard calibration curve was used to 
determine the sample concentrations in the unknown 
samples. 
Results and discussions 
Aspirin and Omeprazole were resolved with resolution 
factor greater than 3.2 with a routine of 8minutes. To 
evaluate assay specificity placebo run and blank run was 
performed and none was found to calculate with Aspirin or 
Omeprazole. The plasma calibration curves were constructed 
using peak height ratios of Aspirin and Omeprazole and their 
concentrations. Linear regression analysis was used to 
calculate slope, intercept and co relation co efficient (r2). The 
linearity over the range of 5-15 µg/ml for Aspirin at 3-8.7 
µg/ml for Omeprazole was found to be satisfactory and 
reproducible over the time, r2 obtained was 0.9994 for 
Aspirin and 0.9998 for Omeprazole. 
 Accuracy of assay determined at Aspirin and Omeprazole 
concentration of over three different days. Accuracy was in 
the range 99.7-102 percent. Relative standard deviation for 
precision data obtained for was 0.23 and 0.34 for Aspirin and 
Omeprazole respectively. The extraction recovery for Aspirin 
and Omeprazole ranged from 99.8 to 100.2 and the result is 
represented in Table-1 &2 
 
 
Table-1 Accuracy and Precision data for Aspirin 
S.N0 
 
Nominal 
concentration(µg/ml) 
Concentration 
found(µg/ml) 
Peak area %recovery 
1 5  5.11  25236  102±0.02  
2 5     (50%)  5.03  25140  100±0.06  
3 5  5.04  25141  100±0.08  
4 10  10.04  51329  100±0.04  
5 10   (100%)  10.03  51328  100±0.03  
6 10  10.08  51335  100±0.08  
7 15 15.01  75423  100±0.01  
8 15     (150%)  15.12  75502  100±0.08  
9 15  15.05  75431  100±0.03  
Standard Deviation 
S.D.=1.36 
 Relative standard 
deviation R.S.D=0.135 
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Table-2 Accuracy and Precision data for Omeprazole 
S.N0 Nominal 
concentration(µg/ml) 
Concentration 
found(µg/ml) 
Peak areas %recovery 
1 3  3.01  12638  100±0.001  
2 3  3.00  12637  100±0.000  
3 3  3.02  12639  100±0.002  
4 5.9  5.88  24966  99±0.66  
5 5.9  5.91  24970  100±0.001  
6 5.9  5.92  24971  100±0.002  
7 8.7  8.73  36795  100±0.034  
8 8.7  8.71  36786  100±0.001  
9 8.7  8.72  36787  100±0.002  
Standard Deviation 
S.D.=0.776 
 Relative standard deviation 
R.S.D=0.132 
 
 
In regard to system suitability parameters ruggedness and 
robustness and significant effect was observed using two 
different HPLC instruments. Further the method was found 
to be reproducible from one analyst to another. 
Fig-3, 4 & 5 shows chromatograms of Aspirin and 
Omeprazole standards; 10, 20, 30 µg/ml concentration of 
Aspirin and 5, 10, 15 µg/ml concentration of Omeprazole. 
 
 
Fig-3 – Chromatogram of Aspirin and Omeprazole (5ug/ml) 
 
Fig-4 – Chromatogram of Aspirin and Omeprazole (10ug/ml) 
 
 
Fig-5– Chromatogram of Aspirin and Omeprazole (15ug/ml) 
 
TABLE-3 represents the peak areas obtained for Aspirin and 
Omeprazole and the concentrations obtained for blood 
sample withdrawls from rats. 
 
Table-3- Peak areas and concentrations of drugs 
 
 Code 5, 10, 15- Concentrations of aspirin prepared. 
 a,b,c,d,e- Blood sample withdrawals at timely basis 
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Fig-6-Calibration curve for various concentrations of Aspirin 
 
 
Fig-7- Time vs concentration curve for Aspirin 
 
 
Fig-8-Calibration curve for various concentrations of 
Omeprazole 
 
Fig-9-Time vs. concentration curve for Omeprazole 
Conclusion 
This is the first report submitted which includes method 
development to determine Aspirin and Omeprazole in rat 
plasma and application of method for pharmacokinetic 
study.  In summary, the Describe method is rapid, sensitive, 
specific, accurate and reproducible. It is of potential value 
for determination of Aspirin and Omeprazole in plasma by 
RP-HPLC in therapeutic levels. The Tmax for Aspirin was 1hr 
20mins and for Omeprazole was 1hr 15mins respectively. 
Prepared Aspirin and Omeprazole levels after oral 
administration of a therapeutic dosage of tablet were 
3.1ug/ml and 1.8µg/ml indicating that the described method 
is potentially suitable for TDM. 
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